Immune reactions induced by interleukin-2 transfected colorectal cancer cells in vitro: Predominant induction of lymphokine-activated killer cells

Journal of Molecular Medicine

Volumn 74, Issue 1, 1996, Pages 43-49

  Lindauer, M ^a,c   Schackert, H K ^b,e   Gebert, J ^b   Rudy, W ^a   Habicht, A ^a   Siebels, M ^a   Meuer, S C ^a,d   Moebius, U ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Adoptive cellular immunotherapy; Colorectal neoplasms; Gene therapy; Interleukin 2

Indexed keywords

ANTIGEN CD54; CD8 ANTIGEN; INTERLEUKIN 2; UNCLASSIFIED DRUG;

ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOLOGY; GENE THERAPY; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; LYMPHOKINE ACTIVATED KILLER CELL; MOLECULAR BIOLOGY;

EID: 0030027691     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00202071     Document Type: Article

References (27)

1. Tepper RI, Mule JJ (1994) Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther 5: 153-164
2. Janssen RAJ, Mulder NH, The TH, de Leij L (1994) The immunobiological effects of interleukin-2 in vivo. Cancer Immunol Immunother 39:207-216
3. Negrier S, Philip TO (1993) Interleukin-2 and lymphokine activated killer (LAK) cells. In: Wagstaff J (ed) The role of interleukin-2 in the treatment of cancer patients. Kluwer, Dordrecht, pp 29-43
4. Stevens EJ, Jacknin L, Robbins PF, Kawakami Y, El Gamil M, Rosenberg SA, Yannelli JR (1995) Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. J Immunol 154:762-771
5. Sznol M (1995) Other cancers. In: DeVita VT, Hellman S, Rosenberg SA (eds) Biologic therapy of cancer, 2nd edn. Lippincott, Philadelphia, pp 269-278
6. Steis RG, Urba WJ, Van der Molen LA, Bookman MA, Smith JW II, Clark JW, Miller RL, Crum ED, Beckner SK, McKnight JE, Ozols RF, Stevenson HC, Young RC, Longo DL (1990) Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity. J Clin Oncol 8:1618-1629
7. Bednarek MA, Engl SA, Gammon MC, Lindquist JA, Porter G, Williamson AR, Zweerink HJ (1991) Soluble HLA-A2.1 restricted peptides that are recognized by influenza virus specific cytotoxic T lymphocytes. J Immunol Methods 139:41-47
8. Deuschle U, Pepperkok R, Wang F, Giordano TJ, McAllister WT, Ansorge W, Bujard H (1989) Regulated expression of foreign genes in mammalian cells under the control of coliphage T3 RNA polymerase and lac represser. Proc Natl Acad Sci USA 86:5400-5404
9. Meuer SC, Hussey RE, Fabbi M, Fox D, Acuto O, Fitzgerald KA, Hodgdon JC, Potentis JP, Schlossman SF, Reinherz EL (1984) An alternative pathway of T-cell activation: a functional role for the 50 kd T11 sheep erythrocyte receptor protein. Cell 36:897-906
10. Hérin M, Lemoine C, Weynants P, Vessière F, Van Pel A, Knuth A, Devos R, Boon T (1987) Production of stable cytolytic T-cell clones directed against autologous human melanoma. Int J Cancer 39:390-396
11. Guarini A, Gansbacher B, Cronin K, Fierro MT, Foa R (1995) IL-2 gene-transduced human HLA-A2 melanoma cells can generate a specific antitumor cytotoxic T-lymphocyte response. Cytokines Mol Ther 1:57-64
12. Schendel DJ, Gansbacher B (1993) Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes: modulation of recognition through retroviral transduction of tumor cells with interleukin 2 complementary DNA and exogenous alpha interferon treatment. Cancer Res 53:4020-4025
13. Gansbacher B, Zier K, Cronin K, Hantzopoulos PA, Bouchard B, Houghton A, Gilboa E, Golde D (1992) Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-gamma in irradiated human melanoma cells. Blood 80:2817-2825
14. Belldegrun A, Tso C-L, Sakata T, Duckett T, Brunda MJ, Barsky HS, Chai J, Kaboo R, Lavey RS, McBride WH, deKernion JB (1993) Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): implications for live cancer vaccines. J Natl Cancer Inst 85:207-216
15. Hathorn RW, Tso CL, Kaboo R, Pang S, Figlin R, Sawyers C, de Kernion JB, Belldegrun A (1994) In vitro modulation of the invasive and metastatic potentials of human renal cell carcinoma by interleukin-2 and/or interferon-alpha gene transfer. Cancer 74:1904-1911
16. Arienti F, Sulé-Suso J, Melani C, Maccalli C, Belli F, Illeini MT, Anichini A, Cascinelli N, Colombo MP, Parmiani G (1994) Interleukin-2 gene-transduced human melanoma cells efficiently stimulate MHC-unrestricted and MHC-restricted autologous lymphocytes. Hum Gene Ther 5:1139-1150
17. Anichini A, Mortarini R, Supino R, Parmiani G (1990) Human melanoma cells with high susceptibility to cell-mediated lysis can be identified on the basis of ICAM-1 phenotype, VLA profile and invasive ability. Int J Cancer 46:508-515
18. Anichini A, Mortarini R, Alberti S, Mantovani A, Parmiani G (1993) T-cell-receptor engagement and tumor ICAM-1 up-regulation are required to by-pass low susceptibility of melanoma cells to autologous CTL-mediated lysis. Int J Cancer 53: 994-1001
19. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B, Frost P (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60:397-403
20. Iwanuma Y, Kato K, Yagita H, Okumura K (1995) Induction of tumor-specific cytotoxic T lymphocytes and natural killer cells by tumor cells transfected with the interleukin-2 gene. Cancer Immunol Immunother 40:17-23
21. Tohmatsu A, Okino T, Stabach P, Padula SJ, Ergin MT, Mukherji B (1993) Analysis of cytolytic effector cell response in vitro against autologous human tumor cells genetically altered to synthesize interleukin-2. Immunol Lett 35:51-58
22. Kärre K (1993) Natural killer cells and the MHC I pathway of peptide presentation. Semin Immunol 5:127-145
23. Habicht A, Lindauer M, Galmbacher P, Rudy W, Gebert J, Schackert H-K, Meuer SC, Moebius U (1995) Developement of irnmunogenic colorectal cancer cell lines for vaccination: expression of CD80 (B7) is not sufficient to restore impaired primary T cell activation in vitro. Eur J Cancer (in press)
24. Yoo Y-K, Heo DS, Hata K, Van Thiel DH, Whiteside TL (1990) Tumor-infiltrating lymphocytes from human colon carcinomas. Functional and phenotypic characteristics after long-term culture in recombinant interleukin 2. Gastroenterology 98:259-268
25. Shimizu Y, Iwatsuki S, Heberman RB, Whiteside TL (1991) Effects of cytokines on in vitro growth of tumor-infiltrating lymphocytes obtained from human primary and metastatic liver tumors. Cancer Immunol Immunother 32:280-288
26. Kawakami Y, Haas GP, Lotze MT (1993) Expansion of tumor-infiltrating lymphocytes from human tumors using the T-cell growth factors interleukin-2 and interleukin-4. J Immunother 14:336-347
27. Zatloukal K, Schneeberger A, Berger M, Schmidt W, Koszik F, Kutil R, Cotten M, Wagner E, Buschle M, Maass G, Payer E, Stingl G, Birnstiel ML (1995) Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. Assessment of critical cellular and molecular parameters. J Immunol 154:3406-3419